Interviews on biotechnology

Interview 12 Jul 2022

Where AI can’t go: PhoreMost’s quest to unearth protein degradation targets

Advances in the AI-powered simulation of proteins are making it easier than ever to discover new drugs. Neil Torbett, CEO of PhoreMost, outlines how the firm’s protein screening technology overcomes current limitations of protein structure predictions, with big applications in the emerging field of protein degradation. Proteins are a critical component to a cell’s activities, […]

July 12, 2022 - 5 minutesmins - By Jonathan Smith

Interview 10 Jan 2022

Leveraging Physics and Quantum Computing to Accelerate Drug Discovery

Novel computational techniques are revolutionizing the way we discover new drugs. Robert Marino, CEO and co-founder of Qubit Pharmaceuticals, discusses the potential of physics to accelerate drug discovery. Paris-based Qubit Pharmaceuticals was established in 2020 to commercialize the work of leading researchers in the computational chemistry space. This field uses computer modeling to predict how […]

January 10, 2022 - 9 minutesmins - By External Contributor

Interview 13 Oct 2021

Thinking About Risk Early on Is Key for Cell Therapy Success

For cell therapy to become mainstream, important issues such as management of risk and quality control need to be addressed, argues Duncan Borthwick, Global Marketing Manager at cell therapy manufacturing firm Solentim. Research and development of cell therapies, along with other advanced medicines like gene therapies, has increased exponentially over the last few years. According […]

October 13, 2021 - 7 minutesmins - By Helen Albert

Interview 23 Aug 2021

Behind the Scenes at Novo Seeds: Building Startups from the Ground up

Søren Møller, Managing Investment Director at Novo Seeds, discusses how the firm’s investment strategy has changed over time to support the creation of biotech startups in the Nordics. Søren Møller has a PhD in molecular biology from the Technical University of Denmark. After spending some time as a postdoc at Stanford University in the US […]

August 23, 2021 - 9 minutesmins - By Helen Albert

Interview 31 May 2021

What’s Ahead for European Biotech Startups After Covid?

With a tumultuous year behind us, 2021 is set out to spell change for many startups in the European biotech ecosystem. Following the Covid-19 pandemic and Brexit, the European biotech startup landscape has seen some big changes over the course of the past year. Jason Mellad and Dan Rooke, CEO and COO of the Cambridge-based […]

May 31, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin

Interview 26 May 2021

Immuno-Oncology: From Science Fiction to the Mainstream

In just a couple of decades, immuno-oncology has taken center stage in the biotechnology industry. We discuss the evolution of the field with experts who have been in it from the very beginning. While immuno-oncology is one of the hottest areas of medicine at the moment, that wasn’t the case 20 years ago. The idea […]

May 26, 2021 - 7 minutesmins - By Clara Rodríguez Fernández

Interview 19 May 2021

Are Biotech Startups Ready for Augmented Reality?

Augmented reality is starting to become a part of the manufacturing process of pharma and biotech companies. Paul Haimes, Vice President of Engineering at PTC, discusses the benefits and challenges to implementing this technology across the biotech industry. Augmented reality (AR) is increasingly being used to maintain and optimize biomanufacturing processes, which can bring economic […]

May 19, 2021 - 8 minutesmins - By Carlos de Rojas

Interview 10 May 2021

The Rollercoaster of Repurposing an Arthritis Drug for Covid-19

The Covid-19 pandemic created an opportunity for many biotech companies to repurpose their existing programs into vaccines and treatments for the novel coronavirus. Cyxone’s CEO Tara Heitner and COO Malin Berthold discuss how they approached this shift at their company. Cyxone was founded in 2015 to develop drugs for rheumatoid arthritis and multiple sclerosis. Based […]

May 10, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin

Interview 21 Apr 2021

Changing Attitudes on Vaccine and Public Health Investment

The Covid-19 pandemic has pushed investment and research into vaccines and public health, but will such interest continue in the long term? Glenn Rockman, founder and Managing Partner of Adjuvant Capital, a VC firm investing in the infectious disease area, believes it will. Rockman did not plan to get into life science investment. With a […]

April 21, 2021 - 5 minutesmins - By Helen Albert

Interview 5 Apr 2021

Base Editing: The Next Frontier in Genome Editing Technology

Jonathan Frampton, Corporate Development Partner at Horizon Discovery, a Perkin Elmer company, shares his insights into the promises of base editing technology. In less than a decade, the advent of CRISPR-Cas9 has made gene editing easier and faster than ever. But CRISPR, as well as earlier genome editing tools, have a series of technical limitations, […]

April 5, 2021 - 4 minutesmins - By Larissa Warneck-Silvestrin

Interview 15 Mar 2021

Developing a Vaccine that Protects Against Covid-19 Variants

Despite the promise of several approved Covid-19 vaccines and the widespread rollout of vaccination programs around the world, recent mutations in the virus causing Covid-19 are raising concern. Can the current vaccines protect against different coronavirus variants? Paul Higham became CEO of the Finnish firm Valo Therapeutics in 2020. The company was founded in 2016 […]

March 15, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin

Interview 3 Mar 2021

The Promises of CRISPR Genome Editing in Biomedicine

Tony Ho, Head of Research and Development at CRISPR Therapeutics, offers his insights into the advantages of CRISPR gene editing over other technologies and what the future holds for the genome editing field. For decades, gene editing required engineering DNA-cutting enzymes, such as zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), for every specific […]

March 3, 2021 - 5 minutesmins - By Larissa Warneck-Silvestrin

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us